Artis BioSolutions to acquire Syngoi Technologies

Artis BioSolutions, a San Diego, USA-based advanced-therapies development and manufacturing company that launched in April this year, today announced that it has entered into a definitive agreement to acquire Syngoi Technologies, a Spanish biotechnology company pioneering novel enzymatic approaches for manufacturing synthetic DNA technologies.

The acquisition will advance Artis’ strategy of building a differentiated platform to accelerate gene-to-drug discovery across a range of therapeutic modalities by adding fast and cost-effective enzymatic-based synthetic DNA manufacturing capabilities. No financial terms of the transaction were disclosed.

Following closing, Artis will establish a US operating presence for Syngoi’s technology through its wholly-owned entity, Landmark Bio, positioning Artis as one of the first platforms to combine good manufacturing practices (GMP) synthetic DNA manufacturing with integrated advanced-therapy capabilities in the USA. Together, Artis, Landmark Bio, and Syngoi will expand the scope of solutions available to advanced-therapy developers in the USA, Europe, and globally, enabling greater flexibility in how critical inputs and manufacturing pathways are brought together.